Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Danielle Schlosser, PhD

    TitleAssistant Professor
    SchoolUCSF School of Medicine
    Address401 Parnassus Ave.
    San Francisco CA 94143
    vCardDownload vCard

      Collapse Biography 
      Collapse Awards and Honors
      NIH/NIMH 2013 - 2018Career Development Award (K23 MH097795)
      NIH/NIMH2013 - 2016Clinical Trial Planning Award (R34 MH100399)
      UCSF, CTSI2014 - 2015Digital Health Research Award
      UCSF, CTSI2013 - 2014Catalyst Award in Digital Health
      UCSF, CTSI2012 - 2013Mobile Health Research Award

      Collapse Overview 
      Collapse Overview
      Dr. Schlosser currently holds the positions of Assistant Professor in the Department of Psychiatry at the University of California, San Francisco, Director of the Digital Health Core in the Department of Psychiatry, and Director of the NIH-funded Digital Research and Interventions for Volitional Enhancement (DRIVE) lab. The goal of her research program is to design, develop, and investigate neuroscience-informed digital health solutions to improve the lives of people with schizophrenia and depression. She has a broad background in clinical psychology, with specific training in behavioral neuroscience, early detection and intervention of psychosis, and digital health research. Dr. Schlosser's research is focused on translating the latest findings in the area of reward processing and psychological determinants of motivation into new interventions to treat individuals with schizophrenia and depression. Her focus in on targeting domains that transcend diagnostic labels, such as motivational states and enhancing outcomes, such as quality of life. More recently, with funding from NIMH, her research was focused on developing a mobile app called PRIME, which was designed to target the motivational system and thereby enhance the drive to improve one's quality of life and health outcomes. Her lab is testing the feasibility and impact of PRIME in two ongoing clinical trials in schizophrenia and they recently completed a pilot trial in depression. Two of the three trials were conducted entirely remotely, one with individuals with depression and the other with individuals recently diagnosed with schizophrenia.

      Collapse ORNG Applications 
      Collapse Websites
      Collapse In The News
      Collapse Awarded Grants
      Collapse Clinical Trials
      Collapse Featured Videos

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Schlosser D, Campellone T, Kim D, Truong B, Vergani S, Ward C, Vinogradov S. Feasibility of PRIME: A Cognitive Neuroscience-Informed Mobile App Intervention to Enhance Motivated Behavior and Improve Quality of Life in Recent Onset Schizophrenia. JMIR Res Protoc. 2016; 5(2):e77. PMID: 27125771.
        View in: PubMed
      2. Loewy R, Fisher M, Schlosser DA, Biagianti B, Stuart B, Mathalon DH, Vinogradov S. Intensive Auditory Cognitive Training Improves Verbal Memory in Adolescents and Young Adults at Clinical High Risk for Psychosis. Schizophr Bull. 2016 Feb 22. PMID: 26903238.
        View in: PubMed
      3. Schlosser DA, Campellone TR, Biagianti B, Delucchi KL, Gard DE, Fulford D, Stuart BK, Fisher M, Loewy RL, Vinogradov S. Modeling the role of negative symptoms in determining social functioning in individuals at clinical high risk of psychosis. Schizophr Res. 2015 Dec; 169(1-3):204-8. PMID: 26530628.
        View in: PubMed
      4. Schlosser DA, Fisher M, Gard D, Fulford D, Loewy RL, Vinogradov S. Motivational deficits in individuals at-risk for psychosis and across the course of schizophrenia. Schizophr Res. 2014 Sep; 158(1-3):52-7. PMID: 25008792; PMCID: PMC4152418.
      5. David J. Miklowitz, Mary P. O’Brien, Danielle A. Schlosser, Jean Addington, Kristin A. Candan, Catherine Marshall, Isabel Domingues, Barbara C. Walsh, Jamie L. Zinberg, Sandra D. De Silva, Michelle Friedman-Yakoobian, Tyrone D. Cannon . . Family-Focused Treatment for Adolescents and Young Adults at High Risk for Psychosis: Results of a Randomized Trial. Journal of the American Academy of Child & Adolescent Psychiatry. 2014.
      6. Miklowitz DJ, O'Brien MP, Schlosser DA, Addington J, Candan KA, Marshall C, Domingues I, Walsh BC, Zinberg JL, De Silva SD, Friedman-Yakoobian M, Cannon TD. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry. 2014 Aug; 53(8):848-58. PMID: 25062592; PMCID: PMC4112074.
      7. Schlosser DA. In people with ultra high risk symptoms, risk of transition to psychotic disorders is highest in the first 2 years. Evid Based Ment Health. 2014 May; 17(2):39. PMID: 24591545; PMCID: PMC4334583.
      8. Fisher M, Loewy R, Carter C, Lee A, Ragland JD, Niendam T, Schlosser D, Pham L, Miskovich T, Vinogradov S. Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia. Schizophr Bull. 2015 Jan; 41(1):250-8. PMID: 24444862; PMCID: PMC4266283 [Available on 01/01/16].
      9. Fisher M, Loewy R, Hardy K, Schlosser D, Vinogradov S. Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia. Annu Rev Clin Psychol. 2013; 9:435-63. PMID: 23297786.
        View in: PubMed
      10. Schlosser DA, Pearson R, Perez VB, Loewy RL. Environmental Risk and Protective Factors and Their Influence on the Emergence of Psychosis. Adolesc Psychiatry (Hilversum). 2012 Apr; 2(2):163-171. PMID: 23125956.
        View in: PubMed
      11. Schlosser DA, Miklowitz DJ, O'Brien MP, De Silva SD, Zinberg JL, Cannon TD. A randomized trial of family focused treatment for adolescents and young adults at risk for psychosis: study rationale, design and methods. Early Interv Psychiatry. 2012 Aug; 6(3):283-91. PMID: 22182667; PMCID: PMC4106700.
      12. Schlosser DA, Jacobson S, Chen Q, Sugar CA, Niendam TA, Li G, Bearden CE, Cannon TD. Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis. Schizophr Bull. 2012 Nov; 38(6):1225-33. PMID: 21825282; PMCID: PMC3494042.
      13. Schlosser DA, Zinberg JL, Loewy RL, Casey-Cannon S, O'Brien MP, Bearden CE, Vinogradov S, Cannon TD. Predicting the longitudinal effects of the family environment on prodromal symptoms and functioning in patients at-risk for psychosis. Schizophr Res. 2010 May; 118(1-3):69-75. PMID: 20171848; PMCID: PMC2856759.
      14. Stuart BK, Schlosser DA. Multifamily group treatment for schizophrenia. Int J Group Psychother. 2009 Jul; 59(3):435-40. PMID: 19548790; PMCID: PMC3397389.
      Danielle's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP